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Abstract 
CD103 (αEβ7) has been shown to be an excellent marker for identifying in vivo activated 
FoxP3
+CD4
+ Treg cells. It is unknown whether re-infusion of in vivo activated donor-type 
CD103
+ Treg cells from recipient can ameliorate ongoing chronic GVHD. Here, we 
showed that, in a chronic GVHD model of DBA/2 (H-2
d) donor to BALB/c (H-2
d) recipient, 
donor-type CD103
+ Treg cells from recipients were much more potent than CD25
hi 
natural Treg cells from donors in reversing clinical signs of GVHD and tissue damage. 
Furthermore, in contrast to CD25
hi natural Treg cells, CD103
+ Treg cells expressed high 
levels of CCR5 but low levels of CD62L and directly migrated to GVHD target tissues. In 
addition, the CD103
+ Treg cells strongly suppressed donor CD4
+ T cell proliferation; they 
also induced apoptosis of in vivo activated CD4
+ T and B cells and significantly reduced 
pathogenic T and B cells in GVHD target tissues. These results indicate that CD103
+ 
Treg cells from chronic GVHD recipients are functional, and re-infusion of the CD103
+ 
Treg cells can shift the balance between Treg cells and pathogenic T cells in chronic 
GVHD recipients and ameliorate ongoing disease. 
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Introduction 
Graft versus host disease (GVHD) is a result of immune attack of host tissues such as 
the  skin, gut, liver, and lung, which is mediated by donor T cells in transplants
1-3. Based 
on different clinical manifestations and histopathology, GVHD can be divided into acute 
and chronic types
4,5. GVHD is considered an exaggerated, undesirable manifestation of 
a normal inflammatory response, in which donor lymphocytes encounter foreign antigens 
in an environment that fosters inflammation
6. Recent studies have shown that this 
exaggerated immune response can be prevented by infusion of natural regulatory (Treg) 
cells
7-10.  
 
Treg cells usually express forkhead box transcription factor(FoxP3)
11. FoxP3
+ Treg cells 
can be divided into thymus-derived natural Treg and periphery-derived adaptive 
Treg
12,13. Natural Treg cells are predominantly CD25
hiCD4
+, although some are CD25
-. 
Based on the expression of CD62L, a selectin that mediates T cell entry into lymph 
nodes
14, the expression of CD103, an αΕβ7 integrin that mediates T cell retention in the 
epithelial compartment
15, and the expression of CCR5, a chemokine receptor that 
mediates T cell migration to inflammatory tissues
16,17, natural Treg cells can be divided 
into CD62L
hiCCR5
-CD103
- naïve Treg cells and  CD62L
lo/-CCR5
+CD103
+ activated Treg 
cells
18,19. Adaptive Treg cells are usually converted from conventional CD4
+ T cells 
during T cell activation under the influence of TGF-β and retinoid acid (RA) and are 
usually CD62L
lo/-CD103
+ 20-24. 
 
Freshly isolated CD62L
hiCD25
hi naïve natural Treg cells and ex vivo anti-CD3/CD28- or 
host APC-activated CD62L
hiCD25
hi natural Treg cells from donors have been shown to 
effectively prevent acute GVHD when co-injected with GVHD-inducing conventional 
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donor T cells
25-29. However, delayed infusion of the Treg cells results in a markedly 
reduced effect, especially in MHC-mismatched recipients
28,30. In addition, freshly isolated 
and in vitro activated donor CD62L
hiCD25
hi natural Treg cells as well as radiation-
resistant host Treg cells have been shown to prevent induction of chronic GVHD
31-33. 
However, it is unclear whether natural Treg cells can ameliorate ongoing chronic GVHD. 
  
 CD103 (αEβ7) has been shown to be an excellent marker for identifying in vivo 
activated FoxP3
+ Treg cells
18,19. Although previous reports have shown that donor 
CD62L
hiCD25
hi naïve Treg cells were more potent than in vivo activated CD62L
lo/-CD25
hi 
Treg cells in preventing acute GVHD, a more recent report has shown that in vivo 
activated CD62L
lo/-CD103
+ Treg cells were more potent than CD62L
hiCD25
hi naïve Treg 
cells in suppressing autoimmune arthritis
18. 
 
Chronic GVHD is considered to be an autoimmune-like disease
4,34. In our current study, 
we observed that, in a chronic GVHD model of DBA/2 donor to BALB/c recipient
31, a 
high percentage of CD103
+ Treg cells were present in the recipients without obvious 
clinical GVHD. Therefore, we compared the therapeutic effect of in vivo activated 
CD103
+ Treg cells with that of freshly isolated or in vitro activated CD62L
hiCD25
hi natural 
Treg cells on the treatment of ongoing chronic GVHD. We observed that donor-type 
CD103
+ Treg cells from chronic GVHD recipients were much more potent than freshly 
isolated or in vitro activated natural Treg cells in ameliorating ongoing chronic GVHD. 
CD103
+ Treg cells induced the apoptosis of in vivo activated pathogenic T and B cells 
and reduced the percentage of pathogenic T cells in GVHD target tissues. These results 
indicate that CD103
+ Treg cells from chronic GVHD recipients are functional, and 
expansion of the CD103
+ Treg cell population in chronic GVHD recipients through re-
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infusion of the Treg cells can shift the balance between Treg cells and pathogenic T cells 
and ameliorate ongoing disease. 
 
Materials and Methods 
Mice: Male DBA/2(H-2
d) and BALB/c (H-2
d) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME), and maintained in a pathogen-free room at City of Hope 
Research Animal Facilities (Duarte, CA). Mice at age 8-12 weeks were used in the 
current studies. Animal use was approved by Institutional Committee of Beckman 
Research Institute of City of Hope(RACC 03008). 
 
Monoclonal antibodies, flow-cytometric analysis and cell sorting. The FITC-,  
phycoerythrin-, APC-, Cy7-APC-, or Cy7-PE conjugated mAb’s to mouse TCRβ, CD5.1, 
B220, Syndecan, CD4, CD103, CD62L, CD25, IL-17, IL-10, and IFN-γ, and the 
apoptosis measuring kit (anti-Annexin V Ab) were all purchased from BD Pharmigen 
(San Diego, CA). Anti-CCR5 was purchased from BioLegend (San Diego, CA). FoxP3 
staining kit was purchased from eBioscience (San Diego, CA). Multiple-color FACS 
analysis and sorting were performed at the City of Hope FACS facility using a 4-laser 
MOFLO immunocytometry system (Dako Cytomation, Fort Collins, Colorado), and data 
were analyzed using FLOWJO software (Tree Star, San Carlos, CA). CD103
+, CD103
-, 
and CD25
hi CD4
+ T cells were sorted by flow cytometry from enriched CD4
+ T cells after 
negative selection with magnetic purification system from Miltenyi Biotec (Auburn, CA), 
as described previously
31. The syndecan
+ and syndecan
-B220
+ B cells were sorted by 
flow cytometry after positive selection of syndecan
+ or B220
+ cells using the magnetic 
purification system. The purity of sorted T and B cells was > 99%.  
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Proliferation assays. Purified CD25
-CD4
+ T cells together with irradiated allogeneic 
CD11c
+ DCs (1 x 10
5 each) were cultured in a U-bottom 96-well plate for 5 days with or 
without graded numbers of Treg cells in co-culture. 
3H-TdR (1 µCi/ml) was added  
18 hours before harvest. Background counts in the wells of responder T cell alone was 
<1000 cpm. The percentage of suppression was calculated using this formula: [CPM of 
culture of Responder x Stimulator - CPM of Culture of Responder x Stimulator x 
Suppressor] ÷ [CPM of culture of Responder x Stimulator] x 100%. 
 
CFSE labeling of Treg cells: CD103
+ Treg and in vitro-expanded Treg cells (1 x 10
6 
each) were labeled with CFSE at 5 µM for 15 minutes as previously described
35. Cells 
were then washed and injected into chronic GVHD recipients.  
  
Histopathology and immunofluorescent  microscopy. Histopathologic specimens from 
skin, kidney, and liver of BALB/c recipients were fixed in formalin before embedding in 
paraffin blocks. Tissue sections were stained with hematoxylin and eosin, and slides 
were examined at 200x or 400x magnification as previously described 
31. 
Immunofluorescent staining was performed with frozen tissue slides. Staining and image 
procedures were previously described
31. Assessment of tissue damage was performed 
based on scoring system previously described
36,37. In brief, skin GVHD was scored on 
the basis of tissue damage in epidermis, dermis, and loss of subcutaneous fat; the 
maximum score is 10.  Liver GVHD was scored on the number of involved tracts and the 
severity of disease in each tract, and the maximum score is 8. Kidney GVHD was 
graded by the glomerular inflammation, proliferation, crescent formation, and necrosis, 
and maximum score is 12. The mean± SE of the score of six recipients in each group 
was calculated. 
 
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From   7
Measurement of autoantibodies in serum and culture supernatants. Anti-dsDNA IgG was 
measured with ELISA as previously described 
31,38,39. Anti-dsDNA titers are expressed in 
units per milliliter, using a reference-positive standard of pooled serum from 6- to 7-
month-old NZB/W mice. A 1:100 dilution of this standard serum was arbitrarily assigned 
a value of 100 U/ml.  
 
Statistical analysis. Proteinuria incidences and survival in different groups were 
compared using the log-rank test with program GraphPad Prism Version 4.0 (Graph Pad 
Software, San Diego, CA). Comparison of two means was analyzed using unpaired two-
tail Student’s t test. 
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Results 
A high percentage of donor-type CD103
+FoxP3
+ Treg cells was present in chimeric 
recipients without chronic GVHD. 
We recently reported that DBA/2 (H-2
d) donor spleen cells induced chronic GVHD in 
sublethal total body irradiation (TBI)-conditioned BALB/c (H-2
d) recipients with 
glomerulonephritis, proteinuria, and sclerodermatous skin damage; the disease induction 
required both donor CD4
+ T and B220
+ B cells in a dose-dependent manner
31. In the 
current study, we also observed that none (0/12) of the recipients given 6.25 x 10
6 donor 
cells developed chronic GVHD with proteinuria, although all (12/12) the recipients given 
100 x 10
6 DBA/2 spleen cells developed the disease and died within 60 days after HCT 
(Fig. 1 A and B). However, the chimerism level in the recipients given 6.25 x 10
6 or 100 x 
10
6 DBA/2 donor spleen cells was similar, and both were close to complete chimerism 
(Fig. 1C). It is unclear why the chimeric recipients given low-dose DBA/2 spleen cells 
showed no clinical signs of chronic GVHD.  
 
It was reported that a high percentage of FoxP3
+ Treg cells among peripheral blood 
mononuclear cells of chronic GVHD patients was correlated to a reduced severity of the 
disease
40,41. It was also reported that in vivo activated Treg cells expressed αEβ7 
integrin CD103
18,19. Therefore, we compared the percentage of CD103
+FoxP3
+ Treg 
cells among donor CD4
+ T cells in the spleen of the recipients with or without chronic 
GVHD. We found that, although the percentage of CD103
+FoxP3
+ Treg cells among 
donor spleen CD4
+ T cells was only 1.5% before HCT, this population was increased 
more than 20-fold and reached up to 45% in recipients without chronic GVHD 20 days 
after HCT (P< 0.001, Fig. 1C and D). On the other hand, the percentage of 
CD103
+FoxP3
+ Treg cells among CD4
+ T cells in the spleen of recipients with chronic 
GVHD was 2-fold lower than that of the recipients without GVHD (P<0.01, Fig.1C and 
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D). It is noteworthy that there was no significant difference regarding the percentage of 
CD103
-FoxP3
+CD4
+ Treg cells among the donors and the recipients with or without 
chronic GVHD (Fig. 1C and D). These results indicate that the presence of high 
percentage of CD103
+FoxP3
+ Treg cells is associated with lack of clinical GVHD in 
recipients given low-dose donor cells, and that the presence of low percentage of 
CD103
+FoxP3
+ Treg cells is associated with the development of chronic GVHD in 
recipients given high-dose donor cells. 
 
Transfer of CD103
+ Treg cells from recipients ameliorated ongoing chronic GVHD. 
First, we tested whether CD103
+ Treg cells in recipients without clinical chronic GVHD 
can ameliorate ongoing disease, sorted CD103
+ Treg cells (1x10
6) from the spleen of 
recipients given 6.25 x10
6 donor spleen cells were injected into recipients given 100 x10
6 
donor cells 20 days after HCT. We found that, while 8/8 of the recipients given PBS 
alone continued to have proteinuria and died by 40 days after PBS injection, 8/8 of the 
recipients treated with CD103
+ Treg cells showed disappearance of proteinuria and all 
survived for more than 100 days (Supplemental Fig. 1). These results indicate that 
CD103
+ Treg cells in recipients without clinical chronic GVHD may block the 
development of the disease. 
 
Next, we tested whether transfer of CD103
+ Treg cells from chronic GVHD recipients 
could ameliorate ongoing chronic GVHD, and freshly isolated and in vitro activated 
CD25
hi natural Treg cells were used in comparison. Although freshly isolated and in vitro 
activated donor CD25
hi natural Treg cells have been shown to effectively prevent chronic 
GVHD
31-33, it is unknown whether the natural Treg cells could ameliorate ongoing chronic 
GVHD. Accordingly, CD103
+ Treg cells were sorted from the spleen of chronic GVHD 
recipients given 100 x 10
6 DBA/2 spleen cells 20 days before. CD25
hi naïve natural Treg 
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cells were sorted from the spleens of DBA/2 donors. In vitro activated and expanded 
CD25
hi natural Treg cells  were from the sorted naïve Treg cells after a 7-day culture with 
anti-CD3/CD28 beads and IL-2 (1000 U/ml) as previously described
42. The expansion 
was about 10 fold (supplemental Fig. 2).  All three types of Treg cells was more than 
98% viable and contained more than 95% of FoxP3
+ cells (Fig. 3A). 
 
Chronic GVHD was induced by injecting DBA/2 spleen cells (100 x 10
6) into irradiated 
BALB/c recipients. 20 days after HCT when all the recipients showed proteinuria, the 
recipients were respectively injected I.V. with CD103
+ Treg, freshly isolated CD25
hi Treg, 
or in vitro expanded CD25
hi Treg cells (1~5 x 10
6). The control mice were injected with 
PBS or CD103
-CD4
+ T cells from chronic GVHD recipients. All the recipients were 
monitored for clinical signs of GVHD and survival for up to 100 days. We found that the 
recipients treated with PBS continued to have proteinuria and all (12/12) died by day 40 
after PBS injection, that is, 60 days after HCT (Fig. 2A). In contrast, injection of CD103
+ 
Treg cells (1 x 10
6) resulted in reversal of proteinuria in 92% (11/12) of the recipients, 
which survived with few signs of chronic GVHD for more than 100 days after Treg cell 
injection. Injection of CD103
-CD4
+ T cells (1 x 10
6) from the recipients did not reverse 
proteinuria or prolong the survival of the recipients, and all (8/8) of the recipients died 
within 40 days of cell injection (data not shown).  
 
In contrast, injection of freshly isolated CD25
hi Treg cells (1 x 10
6 or 5 x 10
6) did not 
reverse proteinuria or significantly prolong the survival in any of the recipients (Fig. 2 A). 
Injection of 1 x 10
6 in vitro expanded CD25
hi Treg cells resulted in reversal of proteinuria 
and long-term survival in only 25% (2/8) of the recipients, and this was 3-fold lower as 
compared with 1 x 10
6 CD103
+ Treg cells(P<0.01), but increasing the dose to 5 x 10
6 
resulted in reversal of proteinuria and long-term survival in 75% (9/12) recipients, which 
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was similar to the result of infusing 1 x 10
6 CD103
+ Treg cells (P=0.2). These results 
indicated that both in vitro and in vivo activated Treg cells can ameliorate ongoing 
chronic GVHD, but in vivo activated Treg cells are much more potent, although freshly 
isolated donor naïve Treg cells have little effect.  
 
Furthermore, we compared the serum levels of pathogenic IgG2a anti-dsDNA 
autoantibodies of recipients treated with CD103
+ Treg cells (1x10
6), in vitro activated 
CD25
hi natural Treg cells (5 x10
6), or freshly isolated natural Treg cells(5 x10
6). We 
found that, 20 days after Treg infusion, the serum anti-dsDNA levels in the recipients 
treated with CD103
+ Treg cells or in vitro activated Treg cells  were reduced 5-fold and 
2-fold, respectively, as compared to the group given PBS only (P<0.01, Fig. 2B). The 
serum anti-dsDNA levels in the recipients given CD103
+ Treg cells were also about 2-
fold lower than that of recipients given in vitro activated Treg cells (P<0.05, Fig. 2B). No 
significant reduction in serum anti-dsDNA levels of the recipients treated with fresh Treg 
cells (data not shown). 
 
Finally, we compared the histopathology of long-term survival recipients treated with 
CD103
+ Treg cells (1x10
6) or in vitro activated CD25
hi natural Treg cells (5 x10
6) with that 
of before treatment. We found that there was a marked reduction in the tissue damage in 
the skin, liver, and kidney of recipients treated with CD103
+ Treg or in vitro activated 
Treg cells, as judged by histopathology score(P<0.01, Fig. 2C and D). Although there 
was no difference observed in the skin and liver of the recipients treated with CD103
+ 
Treg or in vitro activated Treg cells, the kidney tissues of the former recipients looked 
significantly better than that of the latter recipients (P<0.05, Fig. 2C and D). Taken 
together, these results indicate that in vivo activated CD103
+ Treg cells are more 
effective than in vitro activated Treg cells in treating ongoing chronic GVHD.  
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In vivo activated CD103
+FoxP3
+ Treg cells were phenotypically and functionally 
different from the freshly isolated or in vitro activated CD25
hi natural Treg cells.  
Next, we compared the expression of receptors such as CD62L and CCR5 that mediate 
T cell migration into lymphoid or inflammatory GVHD target tissues. We found that the 
majority (>80%) of the freshly isolated and in vitro activated CD25
hi natural Treg cells 
were CD103
- and expressed high levels of CD62L but low levels of CCR5. In contrast, 
CD103
+ Treg cells contained both CD25
hi (>60%) and CD25
- subsets, and the majority 
of them expressed low levels of CD62L, but high levels of CCR5 (Fig. 3A). Furthermore, 
we also compared the tissue distribution of CD103
+ Treg cells and in vitro activated 
CD25
hi natural Treg cells. Consistent with their surface markers, we observed that, 
CFSE-labeled in vitro activated CD25
hi Treg cells predominantly migrated to lymphoid 
tissues, such as the MLN, which was 2-fold higher than that of the in vivo activated 
CD103
+ Treg cells (P<0.01, Fig.3B). In contrast, the in vivo activated CD103
+ Treg cells 
predominantly migrated to inflammatory GVHD target tissues such as the liver, where an 
8-fold higher percentage of CFSE-labeled FoxP3
+ Treg cells were observed, as 
compared to that of in vitro activated CD25
hi Treg cells (P<0.01, Fig.3 B). 
 
Furthermore, we compared the suppressor capacity of the three types of Treg cells in 
vitro. Accordingly, graded numbers of donor Treg cells were added to cultures of sorted 
DBA/2 donor CD25
-CD4
+ T cells stimulated with host DCs. The ratio of Treg/CD25
-CD4
+ 
T effector cells ranged from 1:1 to 1:64. We found that CD103
+ Treg cells were much 
more potent than freshly isolated CD25
hi or in vitro activated CD25
hi Treg cells in 
suppressing donor CD4
+ T proliferation, especially at lower ratios of Treg/effector cells 
(P<0.01, Fig. 3C). Although in vitro activated CD25
hi natural Treg cells were less potent 
than CD103
+ Treg cells, they were significantly more potent than the freshly isolated 
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Treg cells in suppression (P<0.01, Fig. 3C). Furthermore, we tested whether CD103
+ 
Treg cells had any specificity towards host antigens by comparing suppression of donor 
T cell proliferation stimulated with host DCs, MHC matched third-party DCs, and MHC 
mismatched third-party DCs. We found that CD103
+ Treg cells from chronic GVHD 
recipients suppressed donor CD4
+ T proliferation in response to stimulation by both host 
and third-party DCs at higher Treg/effector ratio (>1:16). However, CD103
+ Treg 
suppression was much stronger when host DCs were used as stimulators compared 
with the MHC mismatched third-party DC stimulators at Treg/effector ratios <1:16 
(P<0.01, Fig. 3D), although no difference was observed when MHC matched third-party 
DCs were used as stimulators. In contrast, in vitro activated CD25
hi natural Treg cells 
showed no difference in suppression of donor T cell proliferation in response to host or 
MHC mismatched third-party DC stimulation (Fig. 3E). These results indicate that the 
CD103
+ Treg population includes both antigen specific and non-specific subsets, and the 
host MHC-specific subset is more potent in suppressing donor T cell proliferation in 
response to host APC stimulation. 
 
CD103
+ Treg cells reduced the percentage of syndecan
+ antibody-producing 
plasma cells. 
Since infusion of CD103
+ Treg cells markedly reduced serum levels of pathogenic IgG2a 
anti-dsDNA autoantibodies, we next explored the mechanisms. It was reported that 
syndecan
+ plasma cells were the source of IgG autoantibody in lupus NZB/NZW F1 
mice
43. We tested whether this was the case in chronic GVHD recipients. First, we found 
that the percentage of syndecan
+ cells in the recipients given CD103
+ Treg cells were 
reduced by 4-fold as compared to the untreated recipients given PBS only (P<0.01, Fig. 
4A). Second, as shown in Fig. 4B, depletion of syndecan
+ cells from the spleen cells of 
chronic GVHD recipients markedly reduced the IgG autoantibody production in vitro 
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(P<0.01). Sorted syndecan
+ plasma cells spontaneously secreted IgG anti-dsDNA, and 
CD103
-CD4
+ T cells from chronic GVHD recipients augmented IgG anti-dsDNA 
production by 2-fold (P<0.01), but CD103
+ Treg cells reduced the anti-dsDNA production 
by 2-fold (P<0.01). In addition, CD103
+ Treg cells inhibited the augmentation of the IgG 
anti-dsDNA production mediated by CD103
-CD4
+ T cells (P<0.01). These results 
indicate that the reduction of serum IgG anti-dsDNA levels in recipients treated with 
CD103
+ Treg cells are due in part to a reduction of syndecan
+ IgG antibody-producing B 
cells. 
 
It was recently reported that activated Treg cells could directly kill activated B cells
44.  
We also found that co-culturing syndecan
+ cells or B220
+ B cells from chronic GVHD 
recipients with CD103
+ Treg cells, but not CD103
-CD4
+ T cells, increased the apoptosis 
of syndecan
+ cells by 5-fold and increased the apoptosis of syndecan
-B220
+ B cells by 2-
fold (P<0.01, Fig. 4C). However, CD103
+ Treg cells did not induce apoptosis of non-
activated B220
+ cells from donor spleen (Fig. 4C, bottom row). These results indicate 
that donor-type CD103
+ Treg cells can directly kill donor-type syndecan
+ IgG 
autoantibody-producing plasma cells as well as activated B220
+ B cells. 
 
CD103
+ Treg cells reduced the percentage of donor-type CD4
+ T cells in the spleen 
of chronic GVHD recipients.  
Our previous report showed that donor-type CD4
+ T cells in graft were required for the 
induction of chronic GVHD
31. Because infusion of CD103
+ Treg cells ameliorated 
ongoing chronic GVHD, we compared the change in the percentage of donor-type CD4
+ 
T cells in the spleen of recipients with or without CD103
+ Treg treatment. We found that 
infusion of CD103
+ Treg cells resulted in a 2-fold reduction in total CD4
+ T cells as well 
as FoxP3
-CD44
hiCD62L
loCD4
+ activated T cells as compared to the untreated control 
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recipients (P<0.01, Fig. 5A and B). Furthermore, we found that CD103
+ Treg cells 
augmented the apoptosis of donor-type CD103
-CD4
+ T cells from chronic GVHD 
recipients by 5-fold (P<0.01) but not CD4
+ T cells from donors (P<0.01, Fig. 5B). These 
results suggest that CD103
+ Treg cells can kill activated CD4
+ T cells in chronic GVHD 
recipients, and this may shift the balance between Treg cells and pathogenic T cells. 
 
CD103
+ Treg cells reduced the percentage of pathogenic effector cells in chronic 
GVHD target tissues. 
It was reported that CD4
+ T cells that produced IFN-γ and/or IL-10 were nephritogenic in 
chronic GVHD recipients with proteinuria
45, and CD4
+ T cells that produced IFN-γ and/or 
IL-17 were reported to mediate tissue damages in a GVHD-like autoimmune disorder as 
well as in autoimmune diseases such as EAE and colitis
46-49. Therefore, we tested 
whether infusion of CD103
+ Treg cells reduced the percentage of the pathogenic CD4
+ T 
cells in GVHD target tissues. We first observed that infusion of CD103
+ Treg cells 
resulted in about 2-fold increase in the percentage of CD103
+FoxP3
+ among CD4
+ T 
cells in GVHD target tissues such as the liver and kidney (P<0.01, Fig. 6A). We also 
observed that infusion of CD103
+ Treg cells reduced the percentage of IL-17
+ CD4
+ cells 
by 2-fold in kidney and liver tissues (P<0.01, Fig. 6B). Interestingly, the IFN-γ
+IL-10
+CD4
+ 
T cells were mainly observed in kidney tissues, and infusion of CD103
+ Treg cells led to 
a 10-fold reduction in their percentage among CD4
+ T cells (P<0.01, Fig. 6C).            
IFN-γ
+CD4
+ T cells were also observed in kidney and liver tissues of chronic GVHD 
recipients, and infusion of CD103
+ Treg cells led to about 2-fold reduction in their 
percentage (P<0.01, Fig. 6C). These results indicate that infusion of CD103
+ Treg cells 
can reduce the percentage of infiltrating pathogenic effector cells in chronic GVHD target 
tissues. 
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Discussion 
We have demonstrated here that donor-type CD103
+ Treg cells in chronic GVHD 
recipients are functional, and the in vivo activated CD103
+ Treg cells from chronic GVHD 
recipients are more potent than freshly isolated or in vitro activated CD25
hi natural Treg 
cells from donors in ameliorating ongoing chronic GVHD. The increased therapeutic 
effect of the CD103
+ Treg cells on ongoing chronic GVHD may be associated with their 
expression of high levels of pro-inflammatory chemokine receptors such as CCR5, 
preferential migration to inflammatory GVHD target tissues, antigen-specificity, and 
cytotoxicity against activated T and B cells.  
 
First, the increased therapeutic effect of CD103
+ Treg cells on ongoing chronic GVHD 
may be associated with their ability to enter inflammatory tissue sites of GVHD. We 
observed that the in vivo activated CD103
+ Treg cells from GVHD recipients had 
different migration patterns than the in vitro activated CD25
hi natural Treg cells from 
donors after being transferred into GVHD recipients. The former predominantly migrated 
to GVHD target tissues such as the liver but the latter to lymph nodes such as the MLN. 
This was consistent with the fact that the CD103
+ Treg cells expressed low levels of 
CD62L, but high-levels of CD103 and CCR5. In contrast, the CD25
hi natural Treg cells 
expressed high levels of CD62L, but low levels of CD103 or CCR5. CD62L mediates T 
cell migration to lymph nodes, but CD103 and CCR5 mediates T cell migration to 
inflammatory epithelial tissues
14-16. This observation is consistent with previous report 
about differential tissue migration of CD103
+ and CD103
- natural Treg cells in 
autoimmune mice
18. However, we should point out that, although 1x10
6 in vivo activated 
CD103
+ Treg cells were more effective than 5 x10
6 in vitro activated natural Treg cells in 
treating kidney tissue damage, 5 x 10
6 latter cells were as effective as 1 x10
6 former 
cells in treating liver tissue damage in chronic GVHD recipients. This might be due to the 
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fact that about 70% of in vivo activated CD103
+ Treg cells and 20% of in vitro activated 
natural Treg cells were CCR5
+, and 5 x10
6 latter Treg cells might contain more CCR5
+ 
cells than 1x10
6 former Treg cells. Therefore, it is conceivable that 5 x10
6 in vitro 
activated natural Treg cells can be as effective as 1 x10
6 in vivo activated CD103
+ Treg 
cells in treating liver tissue damage. The less effectiveness of in vitro activated Treg cells 
in treating kidney tissue damage might be due to their lower capacity in killing plasma 
cells that secrete anti-dsDNA autoantibodies that mediate glomerulonephritis
50.  
 
 Second, the increased effect of treating ongoing chronic GVHD with CD103
+ Treg cells 
may be in part associated with host MHC-specific donor Treg cells. We observed that 
the in vivo activated CD103
+ Treg cells, but not the in vitro activated CD25
hi natural Treg 
cells, were more potent in suppressing donor CD4
+ T cell proliferation in response to 
host DC stimulation, as compared to MHC-mismatched third-party DC stimulation. This 
indicates that host MHC-specific Treg cells exist among the CD103
+ Treg cells from 
GVHD recipients, and that they might be important for treating ongoing chronic GVHD. 
This agrees with a previous report that in vitro host APC-activated and expanded 
antigen-specific natural Treg cells were more potent in preventing acute GVHD, as 
compared to anti-CD3/CD28-expanded non-antigen-specific Treg cells
29.  
 
Finally, the increased therapeutic effect on ongoing chronic GVHD by CD103
+ Treg cells 
may be associated with their ability to kill the activated pathogenic T and B cells in 
GVHD recipients. We observed that infusion of CD103
+ Treg cells from GVHD recipients 
resulted in a significant reduction of syndecan
+ plasma cells and CD4
+ T cells in the 
spleen. Infusion of CD103
+ Treg cells resulted in a significant reduction of IFN-γ
+IL-
10
+CD4
+ T cells in kidney as well as IL-17
+ and IFN-γ
+ CD4
+ T cells in liver of the 
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recipients with ongoing chronic GVHD. Syndecan
+ plasma cells secreted anti-dsDNA 
IgG autoantibodies that were previously shown to be pathogenic
50; IFN-γ
+IL-10
+CD4
+ T 
cells were shown to mediate glomerulonephritis
45, and IFN-γ
+ and IL-17
+ CD4
+ T cells 
were shown to mediate chronic inflammation in autoimmune diseases
46-48. 
 
The mechanisms whereby CD103
+ Treg cells reduced the pathogenic T and B cells in 
the spleen and GVHD target tissues are not yet clear. However, we have observed that 
CD103
+ Treg cells directly mediated the apoptosis of activated CD4
+ T and B cells from 
chronic GVHD recipients but not non-activated CD4
+ T and B220
+ B cells from donors in 
in vitro co-culture assays. These results indicate that CD103
+ Treg cells may directly kill 
the pathogenic T and B effector cells in spleen and GVHD target tissues of the 
recipients. We should also point out that suppressor factors (i.e., IL-10,TGF- β, or CTLA-
4) may also play a role in inhibiting the expansion of pathogenic T cells, because it has 
been reported that natural Treg cells ameliorate ongoing colitis via IL-10, TGF- β, or 
CTLA-4
51. 
 
While the mechanisms how CD103
+ Treg cells from GVHD recipients mediate apoptosis 
of activated T and B cells is still unclear, it is likely that they kill the target cells via the 
perforin/granzyme pathway, because we observed that CD103
+ Treg cells express 
higher levels of granzyme-B as compared to freshly isolated natural Treg cells 
(supplemental Fig. 3). It was reported that activated CD25
+ Treg cells mediated 
apoptosis of B blast cells in an antigen-specific manner via the perforin/granzyme B 
pathway
44; human activated CD25
+CD4
+ Treg cells also killed autologous targets 
including CD4
+ and CD8
+ T cells as well as CD14
+ monocytes via the perforin/granzyme 
pathway 
52. However, it is also possible that other pathways are involved. It was reported 
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that CD25
hi natural Treg cells induce cytokine deprivation-mediated apoptosis of effector 
CD4
+ T cells
53, and that activated antigen-specific CD4
-CD8
- Treg cells killed memory 
CD8
+ T cells in a Fas-dependent manner 
54.  
 
The origin of the CD103
+ Treg cells in the chronic GVHD recipients may consist of both 
natural and adaptive Treg cells derived from donor graft, because it was recently 
reported that CD103
+ Treg cells in normal mice are derived from CD25
+ natural Treg 
cells and conversion of conventional CD4
+ T cells
55.  We also observed that depletion of 
CD25
hi natural Treg cells in graft led to a marked reduction of CD103
+ Treg cells in 
recipients (supplemental Fig. 4). These results indicate that CD25
hi natural Treg cells in 
graft can give rise to CD103
+ Treg cells and/or the CD25
hi Treg cells can augment the 
conversion of conventional CD4
+ T cells into CD103
+ Treg cells.  
 
To the best of our knowledge, this is the first demonstration that in vivo activated 
CD103
+ Treg cells have much more potent capacity than freshly isolated or in vitro 
activated natural Treg cells in ameliorating ongoing chronic GVHD; this is also the first 
demonstration that in vivo activated CD103
+ Treg cells can induce apoptosis of 
alloreactive T cells and autoantibody-secreting syndecan
+ plasma cells. These 
observations are of potential clinical interest, because it has been shown that antigen-
specific Treg cells from autoimmune individuals can be expanded in vitro and re-infused 
to ameliorate ongoing diabetes
42.  
 
However, we should point out that it is not yet clear why CD103
+ Treg cells expand in 
the original chronic GVHD recipients but fail to prevent the development of the disease. 
It is possible that, similar to that in a transgenic autoimmune GVHD model
56, pathogenic 
T effector cells and CD103
+ Treg cells expand simultaneously in the recipients after 
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HCT, but the effector cells override the Treg cells, so that GVHD develops. Infusion of 
additional CD103
+ Treg cells may shift the balance. Therefore, we speculate that 
CD103
+ Treg cells from chronic GVHD patients can be expanded in vitro, and re-infusion 
of those cells can ameliorate ongoing chronic GVHD, although it is unknown how many 
cells are required. In addition, clinical therapies that can expand CD103
+ Treg cells in 
vivo may also be effective in treating ongoing chronic GVHD. 
  
In conclusion, our studies have demonstrated that activated CD103
+ Treg cells in 
chronic GVHD recipients are insufficient in number to suppress the pathogenic effector T 
cells, but shifting the balance between them by expanding CD103
+ Treg cell population 
can lead to the amelioration of ongoing chronic GVHD.  
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Figure Legends: 
 
Fig. 1.  Differential percentage of donor-type CD103
+FoxP3
+ Treg cells in chimeric 
recipients with or without chronic GVHD.  A and B: Sublethally irradiated BALB/c 
recipients were transplanted with 6.25 or 100 × 10
6 DBA/2 donor spleen cells. The 
recipients were monitored for proteinuria and survival weekly. There were 12 mice in 
each group combined from 3 replicate experiments. C and D: Spleen cells from 
additional recipients with or without clinical chronic GVHD 20 days after transplantation 
and control DBA/2 donor mice were stained with anti-CD5.1 (donor T cell marker), CD4, 
CD103, and FoxP3. A representative staining pattern of 4 recipients and the percentage 
(mean ± SE) of CD103
+FoxP3
+ and CD103
-FoxP3
+ cells among total CD5.1
+CD4
+ cells 
are shown. 
 
Fig. 2.  CD103
+ Treg cells potently ameliorated ongoing chronic GVHD. Sublethally 
irradiated BALB/c recipients were given 100 × 10
6 DBA/2 donor spleen cells to induce 
chronic GVHD with proteinuria. 20 days after HCT, the chronic GVHD recipients were 
infused with either CD103
+CD4
+ Treg cells from other recipients or freshly isolated or in 
vitro activated CD25
hi natural Treg cells from DBA/2 donors (1- 5 × 10
6 each). The 
control recipients were given PBS only. The recipients were monitored daily for 
proteinuria and survival. A shows the percentage of recipients with reversal of 
proteinuria and percentage of survival.  There were 6-12 recipients in each group 
combined from 2 or 3 replicate experiments. B shows the serum levels of anti-dsDNA 
IgG 20 days after infusion of CD103
+ Treg cells (1 × 10
6), in vitro activated natural Treg 
cells (5 × 10
6) or PBS. C shows the histopathology score (mean ± SE, n=6). D shows the 
histology of skin, liver, and kidney of representative recipients before and after treatment 
with CD103
+ Treg cells or in vitro activated natural Treg cells. Tissues of BALB/c mice 
without HCT are shown as normal control. 
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Fig 3. Differential surface receptors, tissue migration, and suppressor function of 
CD103
+ Treg and CD25
hi natural Treg cells. Naïve CD25
hi natural Treg cells were 
freshly isolated from spleen of DBA/2 donor mice. The in vitro activated and expanded 
CD25
hi natural Treg cells were from sorted naïve CD25
hi natural Treg cells after being 
cultured with anti-CD3/CD28 beads and IL-2 for 7 days. The CD103
+ Treg cells were 
from spleen of day 20 chronic GVHD recipients. A shows the viability as judged by DAPI 
staining, the  expression levels of FoxP3, CD25, CD103, CD62L and CCR5 by freshly 
isolated CD25
hiCD4
+ T cells, in vitro-activated CD25
hiCD4
+ T cells, and in vivo-activated 
CD103
+CD4
+ T cells. One representative is shown of 4 replicated experiments. B, 
CFSE-labeled in vitro-activated CD25
hi natural Treg cells and in vivo-activated CD103
+ 
Treg cells (1 × 10
6 each) were injected I.V. into chronic GVHD recipients, respectively. 
12 hours after injection, the percentage of CFSE
+FoxP3
+ cells among total FoxP3
+ cells 
in the MLN, spleen, and liver was compared. One representative of 4 examined 
recipients in each group is shown. The mean ± SE of CD25
hi natural Treg cells vs 
CD103
+ Treg cells in different tissues are as follows: 10.8 ± 1.2% vs 4.9 ± 1.3% in MLN, 
0.3 ± 0.2% vs 0.5 ± 0.3% in spleen, and 0.4 ± 0.2% vs 3.5 ± 0.8% in liver. C shows 
suppression of host DC-induced donor CD4
+CD25
- T proliferation by freshly isolated and 
in vitro activated CD25
hi natural Treg cells as well as CD103
+ Treg cells. D shows 
CD103
+ Treg cell suppression of donor CD4
+CD25
- T proliferation induced by host, 
MHC-matched third-party DCs,  or MHC-mismatched third-party DCs. E shows in vitro 
activated CD25
hi natural Treg cell suppression of donor CD4
+CD25
- T proliferation 
induced by host or MHC-mismatched third-party DCs. C-E show mean ± SE of 4 
replicated experiments. 
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Fig. 4. CD103
+ Treg cells induced apoptosis of autoantibody-secreting plasma 
cells. A, 20 days after infusion of CD103
+ Treg cells, the spleen cells of the untreated 
and treated recipients were stained for B220 versus syndecan. The percentage of 
syndecan
+ plasma cells and syndecan
-B220
+ B cells are shown beside the gating box. 
One representative of 4 examined recipients is shown. The mean ± SE of syndecan
+ 
cells vs syndecan
-B220
+ cells in the untreated and treated recipients are 4.1 ± 0.4% vs 
1.0 ± 0.2% and 34.5 ± 4.5% vs 33.9 ± 3.8%, respectively. B, Spleen cells (1 × 10
6) of the 
untreated recipients, including whole spleen (SPL), syndecan
+ cell-depleted spleen (Syn
-
-SPL), sorted syndecan
+ cells (Syn
+), sorted syndecan
-B220
+ cells (Syn
-), were co-
cultured with or without sorted CD103
+ or CD103
-CD4
+ T cells (0.2 x 10
6) from the 
spleen of chronic GVHD recipients for 5 days. Anti-dsDNA IgG in the culture supernatant 
was measure by ELISA. The mean ± SE of 4 replicated experiments is shown. “N/A” 
indicates the antibody concentration was below detectable levels. C, Sorted activated 
syndecan
+ and syndecan
-B220
+ B cells from chronic GVHD recipients and B220
+ B cells 
from normal donors were co-cultured with CD103
+ or CD103
-CD4
+ T cells from chronic 
GVHD recipients for 8 hours. Thereafter, the cells were stained for Annexin V versus 
DAPI. The percentage of Annexin V
+DAPI
+ cells among Syn
+ or sydecan
-B220
+ cells is 
shown beside the gating box. One representative of 4 replicated experiments is shown. 
The mean ± SE of the percentage of Annexin V
+DAPI
+ cells among recipient syndecan
+ 
cells are 5.4 ± 1.3%, 28.6 ± 3.6%, and 6.1 ± 1.7%, respectively, when co-cultured alone, 
or co-cultured with CD103
+ or CD103
-CD4
+ T cells. Similarly, the mean ± SE percentage 
among recipient syndecan
-B220
+ cells are 6.5 ± 1.9%, 15.4 ± 2.5%, and 6.8 ± 1.3%, and 
the mean ± SE percentage among donor B220
+ B cells are 5.5 ± 1.3%, 6.3 ± 1.5%, and 
7.7 ± 1.4%. 
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Fig. 5. CD103
+ Treg cells induced apoptosis of activated CD4
+ T cells from chronic 
GVHD recipients. A, 20 days after infusion of CD103
+ Treg cells, the spleen cells of the 
untreated and treated recipients as well as control donor DBA/2 mice were stained for 
CD5.1 versus CD4. The CD5.1
+CD4
+ donor-type T cells were gated. One representative 
of 4 recipients is shown. The mean ± SE of the percentage of CD5.1
+CD4
+ T cells 
among spleen mononuclear cells of untreated and treated recipients are 16.8 ± 3.6%
 
and 8.5 ± 1.6% respectively. B, gated FoxP3
-CD4
+ T cells were shown in CD44 versus 
CD62L. The activated CD44
hiCD62L
loCD4
+ T cells were gated, and the percentage of the 
cells among total FoxP3
-CD4
+ T cells was shown above gated box. One representative 
of 4 recipients is shown. The mean ± SE of the percentage of CD44
hiCD62L
loCD4
+ T 
cells among total FoxP3
-CD4
+ T cells of untreated and treated recipients are 71.0 ± 4.7%
 
and 38.5 ± 6.7%, respectively. C, CD103
-CD4
+ T cells from chronic GVHD recipients or 
normal DBA/2 donors (1 × 10
6 each) were co-cultured with CD103
+ Treg cells from 
chronic GVHD recipients for 8 hours. Thereafter, the cells were stained for Annexin V 
versus DAPI. The percentage of Annexin V
+DAPI
+ cells among CD103
-CD4
+ T cells is 
shown beside the gating box. One representative of 4 experiments is shown. The mean± 
SE of Annexin V
+DAPI
+ cell among CD103
-CD4
+ T cells from chronic GVHD recipients 
with or without CD103
+ Treg cells in co-culture is 25.3 ± 3.3% versus 4.9 ± 1.4%. The 
mean ± SE of Annexin V
+DAPI
+ cells among donor CD103
-CD4
+ T cells with or without 
CD103
+ Treg cells in co-culture is 4.7 ± 1.1% versus 4.2 ± 0.8%.  
 
Fig. 6. CD103
+ Treg cells reduced pathogenic CD4
+ T cells in GVHD target tissues. 
20 days after infusion of CD103
+ Treg cells, mononuclear cells from kidneys and livers of 
untreated and treated recipients were stained for CD4, CD103, IL-17, IL-10, and IFN-γ. 
A, the gated CD4
+ T cells were shown in FoxP3 versus CD103. B, the gated CD4
+ T 
cells were shown in IL-17 versus CD4; and C, gated CD4
+ T cells were show in IL-10 
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versus IFN-γ. One representative of 4 replicated experiments is shown. The mean± SE 
of percentage of FoxP3
+ cells among CD4
+ T cells in kidney and liver of untreated and 
treated recipients is 12.6 ± 2.5% vs 31.7 ± 3.6% and 16.8 ± 2.5% vs 26.9 ± 4.5%, 
respectively. The mean ± SE of percentage of IL-17
+ cells among CD4
+ T cells  in kidney 
and liver of untreated and treated recipients is 3.1 ± 1.7% vs 1.6 ± 0.2% and13.6 ± 2.1% 
vs 7.4 ± 0.7%, respectively. The mean ± SE of percentage of IL-10
+IFN-γ
+ cells among 
CD4
+ T cells  in kidney and liver of untreated and treated recipients is 15.8 ± 3.5% vs 1.8 
± 0.4%, and 0.8 ± 0.3% vs 0.3 ± 0.2%, respectively. The mean ± SE of percentage of 
IFN-γ
+ cells among CD4
+ T cells  in kidney and liver of untreated and treated recipients 
is 7.9 ± 0.9% vs 3.8 ± 0.7% and 19.4 ± 2.8% vs 8.1 ± 1.2%, respectively. 
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